Ireland - English - HPRA (Health Products Regulatory Authority)

interchem ireland ltd - benzylpenicillin procaine ; dihydrostreptomycin sulfate - suspension for injection - 200, 200 milligram(s)/millilitre - penicillins, combinations with other antibacterials - cattle, pigs, sheep - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

huvepharma nv - fenbendazole - suspension for use in drinking water - 200 milligram(s)/millilitre - fenbendazole - chickens - anthelmintic

Ireland - English - HPRA (Health Products Regulatory Authority)

bimeda animal health limited - procaine benzylpenicillin; dihydrostreptomycin sulfate - suspension for injection - 200, 200 milligram(s)/millilitre - penicillins, combinations with other antibacterials

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - captopril, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; stearic acid; maize starch; lactose monohydrate - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recom

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - captopril, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; stearic acid; microcrystalline cellulose; maize starch - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recom

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - dexamethasone sodium phosphate; dexamethasone phenylpropionate - suspension for injection - 1.32/2.67 milligram(s)/millilitre - dexamethasone - cattle, horses - corticosteroid

Ireland - English - HPRA (Health Products Regulatory Authority)

huvepharma nv - fenbendazole - suspension for use in drinking water - 200 milligram(s)/millilitre - fenbendazole - pigs - anthelmintic

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - captopril, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: sodium benzoate; hydrochloric acid; sodium hydroxide; sodium citrate dihydrate; disodium edetate; purified water; citric acid - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recommended that capoten be administered together with a diuretic. 4. diabetic nephropathy: capoten is indicated for the treatment of diabetic nephropathy in patients with type 1 insulin- dependent diabetes mellitus.

Canada - English - Health Canada

quest vitamins a div of purity life health products - beta-carotene - capsule - 25000unit - beta-carotene 25000unit - vitamin a

Canada - English - Health Canada

rheingold food international ltd. - beta-carotene - capsule - 25000unit - beta-carotene 25000unit - vitamin a